MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bioorg.2025.109085

Медицинская библиотека · Bioorganic chemistry · 2025

New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells.

Cursaro Ilaria, Frattaruolo Luca, Scalvini Laura, Contri Chiara, Bichicchi Alessia, Tardiolo Nicola, Tudino Valeria, Rossi Sara, Manti Eugenia Nicol, Cappello Martina, Papulino Chiara, Maellaro Emilia, Marcolongo Paola, Benedetti Rosaria, Altucci Lucia, Varani Katia, Mor Marco, Frosini Maria, Vincenzi Fabrizio, Cappello Anna Rita, Lodola Alessio, Saponara Simona, Butini Stefania, Carullo Gabriele, Gemma Sandra, Campiani Giuseppe

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Histone deacetylases 6 and 8 (HDAC6/8) have emerged as promising therapeutic targets in aggressive neural tumors such as neuroblastoma and glioblastoma. Herein, we report the design, synthesis, and comprehensive biological evaluation of a novel series of hydroxamic acid-based inhibitors (5a-p), featuring nature-inspired vanillyl CAP groups. Structure-activity relationship (SAR) analysis, supported by molecular docking, elucidated the role of CAP, connecting unit, and linker structure, alongside zinc-binding group orientation, on isoform selectivity and potency. Among the series, compound 5o emerged as a highly potent and preferential HDAC6 inhibitor (IC50 = 4.5 nM). In SH-SY5Y neuroblastoma cells, 5o induced dose-dependent α-tubulin hyperacetylation, caspase-3/7 activation that indicates apoptosis, a minor autophagy stimulation and showing negligible cytotoxicity in HEK-293 cells. Furthermore, 5o significantly reduced cell viability in multiple glioblastoma models (U87-MG, T98G, U251-MG), disrupting mitotic progression and promoting G2/M cell cycle arrest, as evidenced by decreased phosphorylation of p-cdc2 (Tyr15). These findings validate the therapeutic relevance of HDAC inhibition in neural tumors and suggest that compound 5o deserves further investigation as an epigenetic modulator in cancer therapy.

Для цитирования: Cursaro Ilaria, Frattaruolo Luca, Scalvini Laura, Contri Chiara, Bichicchi Alessia, Tardiolo Nicola, Tudino Valeria, Rossi Sara, Manti Eugenia Nicol, Cappello Martina, Papulino Chiara, Maellaro Emilia, Marcolongo Paola, Benedetti Rosaria, Altucci Lucia, Varani Katia, Mor Marco, Frosini Maria, Vincenzi Fabrizio, Cappello Anna Rita, Lodola Alessio, Saponara Simona, Butini Stefania, Carullo Gabriele, Gemma Sandra, Campiani Giuseppe. New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells.. Bioorganic chemistry. 2025. DOI: 10.1016/j.bioorg.2025.109085.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.